New York, July 14, 2015 -- Commenting on J&J's 2Q2015 results, Moody's Investors Service stated that J&J's strong diversity and consistent growth rates remain underpinnings of the Aaa credit rating. After adjusting for currency movements, J&J's low-single digit organic growth of 1.7% in the wake of competitive factors and pricing pressure is impressive and speaks to the diversity of J&J's business. All three of J&J's key divisions -- pharmaceuticals, medical devices, and consumer products, achieved positive organic growth rates on a currency-adjusted basis.

Vollständigen Artikel bei Moodys lesen